• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

GAiT.Global

The Global Alliance for iPSC Therapies

  • About GAiT
    • About GAiT
    • Sponsors
      • NYSCF
      • KHiB
      • CCRM
      • INSERM / Cithera /INGESTEM
      • HKU
      • CGT
    • Support Us
  • News & Events
  • Publications
  • Workshops
  • iPSC Quality Assessment Rounds
    • iPSC Quality Assessment Round 2022/2023
      • iPSC Quality Assessment Round 2022 – Document Page
  • Directories
  • Clinical Database
  • Portal Login
You are here: Home / Topics / iPSC Quality Round 2019 – Amalgamated Primary Data Set

iPSC Quality Round 2019 – Amalgamated Primary Data Set

· ·

Home › Forums › iPSC Quality Round 2019 – Amalgamated Primary Data Set

  • This topic has 3 replies, 2 voices, and was last updated 3 years, 7 months ago by Stephen SullivanStephen Sullivan.
Viewing 4 posts - 1 through 4 (of 4 total)
  • Author
    Posts
  • 23rd August 2019 at 1:30 pm #2740
    Stephen SullivanStephen Sullivan
    Keymaster

    Here Participants & Organizers can discuss issues pertinent to the amalgamated primary testing data set. What does the data mean? What courses of action might we consider as a result of the data?

    30th August 2019 at 4:52 pm #2852
    Stephen SullivanStephen Sullivan
    Keymaster

    Remember in discussions not to divulge your own particular codename so data remains anonymized.

     

    30th August 2019 at 5:30 pm #2854
    Steve OhSteve Oh
    Participant

    Good presentation of amalgamated data, Stephen!

    Steve Oh

    30th August 2019 at 5:47 pm #2855
    Stephen SullivanStephen Sullivan
    Keymaster

    There was a large team at SCT, CiRA and NIBSC and ourslves working together. In particular you should thank the following:

    Takafusa Hikichi, Adam Hirst, Rafal Krol, Ito Miyashita, Yuji Arakawa, Jacqueline Barry, Naoko Takasu, Orla O’Shea, Andrew Gaffney, Hanvir Klair and Marc Turner.

    It is great to have the data out to participants. We are interested to watch the discussion progress.

     

    • This reply was modified 3 years, 7 months ago by Stephen SullivanStephen Sullivan.
    • This reply was modified 3 years, 7 months ago by Stephen SullivanStephen Sullivan.
    • This reply was modified 3 years, 7 months ago by Stephen SullivanStephen Sullivan.
    • This reply was modified 3 years, 7 months ago by Stephen SullivanStephen Sullivan.
  • Author
    Posts
Viewing 4 posts - 1 through 4 (of 4 total)
  • You must be logged in to reply to this topic.
Log In

Primary Sidebar

Search Users

Forum Search

More results...

Search Forums
Sample Label 1
Sample Label 2
Sample Label 3
Filter by Topic Tags
banking requirements
cell culture automation iPSC manufacturing scale up
comparability iPSC therapeutic CQA critical quality attribute
critical quality attributes
critical quality attributes potency iPSC testing
Database design
database front end design
donor consent
efficacy
establishment gmp
GAiTpost newsletter
iPSC IP license
manufacturing cell substrates
manufacturing comparability
manufacturing scale up therapeutic development
Melboune
Melbourne
Personal data GDPR
QC manuscript
Quality Survey
regulation
standard value use cell therapy development
standardisation control cell therapy
test
Content from
Content to
Advanced Search

Secondary Sidebar

Recent Topics

  • Regulatory Considerations for clinical-grade iPSC
  • iPSC Quality Round 2019 – Amalgamated Primary Data Set
  • Donor Consent
  • Establishing iPSCs under GMP conditions
  • Testing for efficacy

Discussion Tags

banking requirements cell culture automation iPSC manufacturing scale up comparability iPSC therapeutic CQA critical quality attribute critical quality attributes critical quality attributes potency iPSC testing Database design database front end design donor consent efficacy establishment gmp GAiTpost newsletter iPSC IP license manufacturing cell substrates manufacturing comparability manufacturing scale up therapeutic development Personal data GDPR QC manuscript Quality Survey regulation standardisation control cell therapy standard value use cell therapy development

Invite Users to Site

Invite another user onto the GAiT Website
Invite Users

Social media

Follow us on social media

GAiT LinkedIn GAit Sound Cloud GAiT Twitter

 

 

Newsletter





© 2023 GAiT. All Rights reserved. Web Design by Conceptstore
  • Home
  • Portal Login